Resmed Inc
RSMDF- Exchange
- OTC
- Industry
- Surgical & Medical Instruments & Apparatus
- SEC CIK
- 0000943819
In the last 90 days, Resmed Inc insiders filed 0 open-market purchases and 5 sales; 1 institution reported holding it in 13F filings for Q2 2026, worth $1.17K in total; no superinvestor holds it.
Other share classesRMD
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Resmed Inc insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 5 filings
- 2 insiders, $5.26M in total
- Insiders trading
- 2
- Net value
- −$5.26M
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Resmed Inc, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Farrell Michael J. | Chairman and CEO | 466,256 | Sep 10, 2026 | 15 |
| Farrell Peter C | Director | 51,803 | Sep 4, 2026 | 11 |
| Rider Michael J | Global General Counsel | 9,488 | Jun 3, 2026 | 6 |
| Sandercock Brett | Chief Financial Officer | 83,495 | May 4, 2026 | 9 |
| De Witte Jan | Director | 4,261 | Nov 26, 2025 | 3 |
| Mowad-Nassar Nicole | Director | 777 | Nov 26, 2025 | 2 |
| Taylor Ronald R | Director | 24,771 | Nov 24, 2025 | 1 |
| Burt Carol | Director | 2,156 | Nov 24, 2025 | 1 |
| Drexler Karen | Director | 10,602 | Nov 24, 2025 | 1 |
| Gill Harjit | Director | 10,940 | Nov 24, 2025 | 2 |
| Leong Justin | Chief Product Officer | 29,028 | Nov 24, 2025 | 1 |
| DelOrefice Christopher | Director | 2,423 | Nov 24, 2025 | 1 |
| Tan Desney | Director | 6,002 | Nov 24, 2025 | 1 |
| Hernandez John | Director | 5,118 | Nov 24, 2025 | 1 |
| Sulpizio Richard | Director | 17,796 | Nov 21, 2025 | 1 |
| Ghoshal Kaushik | Chief Commercial Officer, SaaS | 9,725 | Aug 5, 2025 | 0 |
| Douglas Robert Andrew | Special Advisor | 13,849 | Jan 3, 2024 | 0 |
| Blaise Lucile | President, Sleep & RC Business | 10,305 | Nov 16, 2023 | 0 |
| Pendarvis David | Chief Administrative Officer | 89,729 | Jun 30, 2023 | 0 |
| Hollingshead James | President, Sleep Business | 76,721 | Dec 1, 2021 | 0 |
| Resmed Inc | Director | 13,823 | Nov 22, 2021 | 0 |
| Sodhi Rajwant | President, SaaS Business | 26,731 | Oct 14, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 3, 2026 (view filing) | Feb 2 | 1 day | Sandercock BrettChief Financial Officer | SSaleResMed Common Stock | −1.00K | $257.03 | −$257.0K | −1.2%85.5K after | 10b5-1 |
| Feb 6, 2026 (view filing) | Feb 4 | 2 days | Rider Michael JGlobal General Counsel | SSaleResMed Common Stock | −50 | $260.00 | −$13.0K | −0.5%9.69K after | 10b5-1 |
| Feb 6, 2026 (view filing) | Feb 4 | 2 days | Farrell Peter CDirector | SSaleResMed Common Stock | −2.00K | $251.31 | −$502.6K | −3.0%64.8K after | 10b5-1 |
| Feb 10, 2026 (view filing) | Feb 9 | 1 day | Farrell Michael J.Chairman and CEO | SSaleResMed Common Stock | −4.99K | $273.78 | −$1.37M | −1.1%466.2K after | 10b5-1 |
| Mar 3, 2026 (view filing) | Mar 2 | 1 day | Sandercock BrettChief Financial Officer | SSaleResMed Common Stock | −1.00K | $254.30 | −$254.3K | −1.2%84.5K after | 10b5-1 |
| Mar 5, 2026 (view filing) | Mar 4 | 1 day | Farrell Peter CDirector | SSaleResMed Common Stock | −2.00K | $260.22 | −$520.4K | −3.1%62.8K after | 10b5-1 |
| Mar 11, 2026 (view filing) | Mar 9 | 2 days | Farrell Michael J.Chairman and CEO | SSaleResMed Common Stock | −4.99K | $251.03 | −$1.25M | −1.1%466.2K after | 10b5-1 |
| Apr 2, 2026 (view filing) | Apr 1 | 1 day | Farrell Peter CDirector | SSaleResMed Common Stock | −2.00K | $225.00 | −$450.0K | −3.2%60.8K after | 10b5-1 |
| Apr 3, 2026 (view filing) | Apr 1 | 2 days | Sandercock BrettChief Financial Officer | SSaleResMed Common Stock | −1.00K | $224.31 | −$224.3K | −1.2%83.5K after | 10b5-1 |
| Apr 9, 2026 (view filing) | Apr 7 | 2 days | Farrell Michael J.Chairman and CEO | SSaleResMed Common Stock | −4.99K | $225.50 | −$1.13M | −1.1%466.2K after | 10b5-1 |
| May 11, 2026 (view filing) | May 7 | 4 days | Farrell Michael J.Chairman and CEO | SSaleResMed Common Stock | −4.99K | $207.82 | −$1.04M | −1.1%466.2K after | 10b5-1 |
| Jun 9, 2026 (view filing) | Jun 8 | 1 day | Farrell Michael J.Chairman and CEO | SSaleResMed Common Stock | −4.99K | $193.96 | −$968.1K | −1.1%466.3K after | 10b5-1 |
| Jul 9, 2026 (view filing)7:40 AM ET | Jul 7 | 2 days | Farrell Michael J.Chairman and CEO | SSaleResMed Common Stock | −4.99K | $218.55 | −$1.09M | −1.1%466.2K after | 10b5-1 |
| Aug 6, 2026 (view filing)2:29 PM ET | Aug 5 | 1 day | Farrell Peter CDirector | SSaleResMed Common Stock | −8.00K | $225.00 | −$1.80M | −13.2%52.8K after | 10b5-1 |
| Aug 11, 2026 (view filing)6:30 AM ET | Aug 7 | 4 days | Farrell Michael J.Chairman and CEO | SSaleResMed Common Stock | −4.99K | $205.69 | −$1.03M | −1.1%466.3K after | 10b5-1 |
| Sep 4, 2026 (view filing)6:30 AM ET | Sep 2 | 2 days | Farrell Peter CDirector | SSaleResMed Common Stock | −970 | $234.73 | −$227.7K | −1.8%51.8K after | 10b5-1 |
| Sep 10, 2026 (view filing)6:40 AM ET | Sep 8 | 2 days | Farrell Michael J.Chairman and CEO | SSaleResMed Common Stock | −4.99K | $222.44 | −$1.11M | −1.1%466.3K after | 10b5-1 |